Orano med

Executive Summary

Orano Med is a private biotechnology company pioneering targeted alpha therapies (TATs) for oncology using lead-212 (²¹²Pb), a potent alpha-emitting radioisotope. Founded in 2018 and headquartered in Cambridge, MA, the company leverages ²¹²Pb's short half-life and high linear energy transfer to deliver tumor-specific cytotoxicity while minimizing off-target effects. Unlike beta-emitting radioligands, alpha particles offer superior DNA double-strand break induction, potentially overcoming resistance mechanisms. Orano Med operates dedicated preclinical laboratories and an industrial-scale production platform for ²¹²Pb, positioning itself as an integrated developer and manufacturer. Currently in the preclinical stage, Orano Med has not disclosed specific drug candidates or clinical timelines. The company's proprietary platform aims to generate a pipeline of radioligand therapies for various solid tumors. Key upcoming catalysts include potential IND filings, first-in-human trial initiations, or strategic partnerships to secure isotope supply or co-develop assets. While the TAT field is competitive, Orano Med's focus on ²¹²Pb and internal manufacturing capabilities differentiate it. Proximity to major biotech hubs and experienced leadership enhance its prospects, though preclinical stage yields inherent uncertainty.

Upcoming Catalysts (preview)

• Q1 2027First-in-human trial initiation for lead candidate60% success
• Q3 2026Strategic partnership for isotope supply or co-development70% success
• Q4 2026IND filing for lead candidate65% success